Enteric Disease Testing Market by Product, Disease Type, Diagnostic Techniques, Testing Site

List of Tables

The Enteric Disease Testing Market was valued at USD 4.31 billion in 2023, expected to reach USD 4.54 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 6.26 billion by 2030.

The scope of enteric disease testing encompasses diagnostic methods used to identify infections within the gastrointestinal tract caused by viruses, bacteria, and parasites. This testing is crucial for both public health surveillance and clinical management, enabling timely interventions to control outbreaks and ensure appropriate medical treatment. Applications are widespread and include diagnostic labs, hospitals, clinics, and public health organizations. End-use sectors range from healthcare facilities focusing on patient care to research institutions developing advanced diagnostic tools.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.31 billion
Estimated Year [2024]	USD 4.54 billion
Forecast Year [2030]	USD 6.26 billion
CAGR (%)	5.47%

Market growth is significantly influenced by factors such as rising incidence of enteric diseases due to more global travel and changes in climate, which affect pathogen distribution. The demand for rapid, accurate diagnostic methods is increasing, driven by technological advancements in molecular diagnostics and the rising awareness about the importance of early detection and management of infections. Opportunities abound in the innovation of non-invasive testing methods and the development of point-of-care testing kits, which cater to remote or resource-poor settings where traditional lab infrastructure may be lacking.

However, the market faces limitations, including high costs associated with advanced diagnostic technologies and a lack of skilled personnel to operate sophisticated equipment, particularly in developing regions. Regulatory hurdles can also slow the introduction of new testing solutions. Challenges such as the need for extensive validation of novel tests and the variability in pathogen presentation complicate standardization efforts.

Innovation should focus on enhancing the sensitivity and specificity of tests while reducing costs and improving accessibility. Research into multiplex assays capable of detecting multiple pathogens in a single test is particularly promising. Additionally, developing portable, easy-to-use devices for field testing in outbreak scenarios can broaden market reach.

The market is competitive but dynamic, defined by ongoing research and technological progress that promises to address current challenges while driving further growth. Strategic partnerships, mergers, and acquisitions, along with a focus on developing cost-efficient solutions, will be crucial for business expansion in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Enteric Disease Testing Market

The Enteric Disease Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of enteric diseases due to poor sanitation and contaminated water supplies
- Technological innovations in diagnostic tests offer greater sensitivity, specificity, and faster results
- Governmental and non-governmental organizations' initiatives to control infectious diseases
Market Restraints
- High cost of advanced tests and the lack of infrastructure in emerging countries
Market Opportunities
- Increasing investment in healthcare infrastructure and the focus on preventive diagnostics
- Strategic partnerships and collaborations for R&D activities and market expansion
Market Challenges
- Regulations concerning the approval and commercialization of product

Porter's Five Forces: A Strategic Tool for Navigating the Enteric Disease Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Enteric Disease Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Enteric Disease Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Enteric Disease Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Enteric Disease Testing Market

A detailed market share analysis in the Enteric Disease Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Enteric Disease Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Enteric Disease Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Enteric Disease Testing Market

A strategic analysis of the Enteric Disease Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Enteric Disease Testing Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Als Limited, Asure Quality, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerica Inc., bioMerieux SA, Bureau Veritas Group, Cepheid Inc., Coris BioConcept SPRL, DiaSorin, Eurofins Scientific SE, Hardy Diagnostics, Intertek Group PLC, Merck & Co., Inc., Merck KGAA, Meridian Bioscience Inc., Merieux NutriSciences Corporation, Neogen Corporation, Nova Biologicals, Perkinelmer, Inc., Qiagen N.V., Quest Diagnostics, Romer Labs Division Holding GmbH, SGS SA, Symbio Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and TUV SUD AG.

Market Segmentation & Coverage

This research report categorizes the Enteric Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Consumables, Kits, and Reagents.
Based on Disease Type, market is studied across Bacterial, Parasitic, and Viral. The Bacterial is further studied across Cholera, Escherichia coli, and Salmonellosis.
Based on Diagnostic Techniques, market is studied across Immunoassays, Molecular Diagnostics, and Rapid Diagnostics. The Molecular Diagnostics is further studied across PCR and Real-time PCR. The Rapid Diagnostics is further studied across Dipsticks and Lateral Flow Assays.
Based on Testing Site, market is studied across In-Hospital, Point-of-Care, and Standalone Laboratories.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-732E7CFCB4A5

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of enteric diseases due to poor sanitation and contaminated water supplies
  - 5.1.1.2. Technological innovations in diagnostic tests offer greater sensitivity, specificity, and faster results
  - 5.1.1.3. Governmental and non-governmental organizations' initiatives to control infectious diseases
- 5.1.2. Restraints
  - 5.1.2.1. High cost of advanced tests and the lack of infrastructure in emerging countries
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing investment in healthcare infrastructure and the focus on preventive diagnostics
  - 5.1.3.2. Strategic partnerships and collaborations for R&D activities and market expansion
- 5.1.4. Challenges
  - 5.1.4.1. Regulations concerning the approval and commercialization of product
5.2. Market Segmentation Analysis
- 5.2.1. Disease Type: Increasing preference for multiplex and molecular diagnostic methods for bacterial testing
- 5.2.2. Testing Site: Need for rapid diagnostics crucial for immediate patient care in hospitals
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Enteric Disease Testing Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Kits
6.4. Reagents

7. Enteric Disease Testing Market, by Disease Type

7.1. Introduction
7.2. Bacterial
- 7.2.1. Cholera
- 7.2.2. Escherichia coli
- 7.2.3. Salmonellosis
7.3. Parasitic
7.4. Viral

8. Enteric Disease Testing Market, by Diagnostic Techniques

8.1. Introduction
8.2. Immunoassays
8.3. Molecular Diagnostics
- 8.3.1. PCR
- 8.3.2. Real-time PCR
8.4. Rapid Diagnostics
- 8.4.1. Dipsticks
- 8.4.2. Lateral Flow Assays

9. Enteric Disease Testing Market, by Testing Site

9.1. Introduction
9.2. In-Hospital
9.3. Point-of-Care
9.4. Standalone Laboratories

10. Americas Enteric Disease Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Enteric Disease Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Enteric Disease Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. FDA Clears MeMed BV Direct from Whole Blood
- 13.3.2. Avacta Acquires European Diagnostic Test Maker
- 13.3.3. Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 3M Company
2. Abbott Laboratories
3. Als Limited
4. Asure Quality
5. Becton, Dickinson and Company
6. Bio-Rad Laboratories, Inc.
7. Biomerica Inc.
8. bioMerieux SA
9. Bureau Veritas Group
10. Cepheid Inc.
11. Coris BioConcept SPRL
12. DiaSorin
13. Eurofins Scientific SE
14. Hardy Diagnostics
15. Intertek Group PLC
16. Merck & Co., Inc.
17. Merck KGAA
18. Meridian Bioscience Inc.
19. Merieux NutriSciences Corporation
20. Neogen Corporation
21. Nova Biologicals
22. Perkinelmer, Inc.
23. Qiagen N.V.
24. Quest Diagnostics
25. Romer Labs Division Holding GmbH
26. SGS SA
27. Symbio Laboratories
28. Thermo Fisher Scientific Inc.
29. Trinity Biotech PLC
30. TUV SUD AG